Plasma Proteome adaptations in Feminising Gender Affirming Hormone therapy and Pregnancy

ABSTRACT: The dataset consists of longitudinal plasma proteomic data was generated using the Olink proteomics platform in plasma from transgender individuals receiving feminizing gender-affirming hormone therapy (GAHT). There were two treatment arms in the clinical trial that received different anti-androgens to inhibit testosterone. This included a cyproterone acetate ("CPA") group (n=20) and a spironolactone ("SPIRO") group (n=20). Proteomics was measured in plasma at baseline and 6 months following feminizing GAHT. Additionally data in a cross-sectional pregnancy cohort at first and third trimester, as well as a cis female and cis male control were generated.

INSTRUMENT(S):

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Blood Plasma

SUBMITTER: Boris Novakovic  

LAB HEAD: Boris Novakovic

PROVIDER: PAD000016 | Pride | 2025-09-17

REPOSITORIES: Pride